Title |
-
Possible Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Reducing Effects of Blood Glucose and also Blood Pressure
|
Creator |
|
Rights |
-
© 2020 Bando H. This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
|
Subject |
-
Other
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
-
Other
Phlorizin
-
Other
Antihypertensive Agents (AHA)
-
Other
Cardiovascular Event
-
Other
Blood Pressure
|
Description |
-
Other
Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) has been in focus for the pharmacotherapy of diabetes. SGLT2i contributes to decreasing blood pressure (BP) to some degree. BP changes were analyzed in 4 well-known mega-studies. They are Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study, Canagliflozin cardioVascular Assessment Study (CANVAS), Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) and Dapagliflozin Effect on CardiovascuLAR Events (DECLARE)-TIMI 58. The ultimate goal of antihypertensive and hypoglycemic agents is not the achievement of target values, but the suppression of cardiovascular events. SGLT-2i show excellent strategy for event suppression and adjunct method for hypertension.
|
Publisher |
Asploro
|
Date |
|
Language |
|
Resource Type |
journal article |
Version Type |
VoR |
Identifier |
URI
http://repo.lib.tokushima-u.ac.jp/115284
|
Relation |
-
isIdenticalTo
DOI
https://doi.org/10.36502/2020/ASJBCCR.6210
|
Journal |
-
-
Asploro Journal of Biomedical and Clinical Case Reports
-
Volume Number3
Issue Number3
Page Start186
Page End190
|
File |
|
Oaidate |
2023-06-26 |